UY35874A - Un proceso para la preparación de una composición de proteínas pegiladas - Google Patents
Un proceso para la preparación de una composición de proteínas pegiladasInfo
- Publication number
- UY35874A UY35874A UY0001035874A UY35874A UY35874A UY 35874 A UY35874 A UY 35874A UY 0001035874 A UY0001035874 A UY 0001035874A UY 35874 A UY35874 A UY 35874A UY 35874 A UY35874 A UY 35874A
- Authority
- UY
- Uruguay
- Prior art keywords
- proteins
- pegilated
- preparation
- composition
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
- C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Abstract
Esta invención se ubica en el campo de la pegilación de proteínas. En particular, se refiere a un método para pegilar proteínas terapéuticas. La invención también se refiere al uso de dichos polipép tidos terapéuticos pegilados para el tratamiento de enfermedades y trastornos musculares
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361915090P | 2013-12-12 | 2013-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35874A true UY35874A (es) | 2015-07-31 |
Family
ID=52432861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035874A UY35874A (es) | 2013-12-12 | 2014-12-10 | Un proceso para la preparación de una composición de proteínas pegiladas |
Country Status (20)
Country | Link |
---|---|
US (1) | US20160058878A1 (es) |
EP (1) | EP3079724A1 (es) |
JP (1) | JP2017502005A (es) |
KR (1) | KR20160095133A (es) |
CN (1) | CN106029105A (es) |
AP (1) | AP2016009244A0 (es) |
AR (1) | AR098732A1 (es) |
AU (1) | AU2014362992A1 (es) |
BR (1) | BR112016013121A2 (es) |
CA (1) | CA2933640A1 (es) |
CU (1) | CU20160082A7 (es) |
EA (1) | EA201691220A1 (es) |
IL (1) | IL246037A0 (es) |
MX (1) | MX2016007662A (es) |
PH (1) | PH12016501132A1 (es) |
SG (1) | SG11201604355WA (es) |
TN (1) | TN2016000214A1 (es) |
TW (1) | TW201526908A (es) |
UY (1) | UY35874A (es) |
WO (1) | WO2015087276A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2935320T1 (sl) | 2012-12-18 | 2019-12-31 | Novartis Ag | Stabilizirani polipeptidi inzulinu podobnega rastnega faktorja |
EP3876996A1 (en) * | 2018-11-05 | 2021-09-15 | Bristol-Myers Squibb Company | Method for purifying pegylated protein |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
EP1141014B1 (en) | 1999-01-06 | 2004-12-08 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variant |
DE60029968T2 (de) | 1999-08-09 | 2006-12-21 | Sandoz Ag | Proteinherstellung |
CZ303341B6 (cs) | 1999-08-09 | 2012-08-08 | Sandoz Ag | Molekula nukleové kyseliny kódující fúzní protein, který obsahuje polypeptid s autoproteolytickou aktivitou |
TWI364295B (en) * | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
JP4988599B2 (ja) | 2005-01-07 | 2012-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Igf−1融合ポリペプチドおよびその治療的使用 |
JP5101492B2 (ja) | 2005-04-26 | 2012-12-19 | サンド・アクチエンゲゼルシヤフト | 融合タンパク質の自己タンパク質分解切断による組換えタンパク質の産生 |
BRPI0712052A2 (pt) * | 2006-06-09 | 2012-01-10 | Novartis Ag | polipeptìdeos de fator de crescimento tipo insulina estabilizados |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
MX2010010495A (es) | 2008-04-03 | 2010-10-15 | Hoffmann La Roche | Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares. |
JP5766179B2 (ja) | 2009-04-27 | 2015-08-19 | ノバルティス アーゲー | 筋肉増殖を増加させるための組成物および方法 |
-
2014
- 2014-12-10 UY UY0001035874A patent/UY35874A/es not_active Application Discontinuation
- 2014-12-11 CN CN201480075319.9A patent/CN106029105A/zh active Pending
- 2014-12-11 KR KR1020167018244A patent/KR20160095133A/ko not_active Application Discontinuation
- 2014-12-11 AU AU2014362992A patent/AU2014362992A1/en not_active Abandoned
- 2014-12-11 TN TN2016000214A patent/TN2016000214A1/en unknown
- 2014-12-11 CA CA2933640A patent/CA2933640A1/en not_active Abandoned
- 2014-12-11 US US14/567,430 patent/US20160058878A1/en not_active Abandoned
- 2014-12-11 WO PCT/IB2014/066806 patent/WO2015087276A1/en active Application Filing
- 2014-12-11 TW TW103143360A patent/TW201526908A/zh unknown
- 2014-12-11 AP AP2016009244A patent/AP2016009244A0/en unknown
- 2014-12-11 MX MX2016007662A patent/MX2016007662A/es unknown
- 2014-12-11 SG SG11201604355WA patent/SG11201604355WA/en unknown
- 2014-12-11 JP JP2016538557A patent/JP2017502005A/ja active Pending
- 2014-12-11 EA EA201691220A patent/EA201691220A1/ru unknown
- 2014-12-11 BR BR112016013121A patent/BR112016013121A2/pt not_active Application Discontinuation
- 2014-12-11 EP EP14831080.8A patent/EP3079724A1/en not_active Withdrawn
- 2014-12-12 AR ARP140104631A patent/AR098732A1/es unknown
-
2016
- 2016-06-05 IL IL246037A patent/IL246037A0/en unknown
- 2016-06-10 PH PH12016501132A patent/PH12016501132A1/en unknown
- 2016-06-10 CU CUP2016000082A patent/CU20160082A7/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160095133A (ko) | 2016-08-10 |
AP2016009244A0 (en) | 2016-05-31 |
PH12016501132A1 (en) | 2016-08-15 |
IL246037A0 (en) | 2016-07-31 |
TN2016000214A1 (en) | 2017-10-06 |
EA201691220A1 (ru) | 2016-10-31 |
JP2017502005A (ja) | 2017-01-19 |
CN106029105A (zh) | 2016-10-12 |
BR112016013121A2 (pt) | 2017-09-26 |
TW201526908A (zh) | 2015-07-16 |
SG11201604355WA (en) | 2016-07-28 |
WO2015087276A1 (en) | 2015-06-18 |
CU20160082A7 (es) | 2016-11-29 |
MX2016007662A (es) | 2017-02-20 |
US20160058878A1 (en) | 2016-03-03 |
EP3079724A1 (en) | 2016-10-19 |
CA2933640A1 (en) | 2015-06-18 |
AU2014362992A1 (en) | 2016-06-16 |
AR098732A1 (es) | 2016-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
EA201270722A1 (ru) | Формы рифаксимина и их применение | |
EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
MX2021007268A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
LT3377637T (lt) | Kompozicijos, skirtos panaudoti žaizdų, sutrikimų ir odos ligų gydymo būduose | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
BR112016006564A2 (pt) | proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
EA201591839A1 (ru) | Терапевтические пептиды | |
EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
HK1246669A1 (zh) | 人血清白蛋白低分子量組分在疾病治療中的應用 | |
CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
BR112014016389A8 (pt) | composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas | |
GT201500168A (es) | Polipéptidos estabilizados del factor de crecimiento tipo insulina | |
EA201391440A1 (ru) | Производные пиразолопиримидина | |
EA201890225A1 (ru) | Слитые белки, которые связываются с fc рецепторами человека | |
GT200900319A (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
CU20160082A7 (es) | Un proceso para la preparación de una composición de proteínas pegiladas | |
BR112015028890A2 (pt) | derivados de piridona para o tratamento de infecções virais e outras doenças | |
CL2015001520A1 (es) | Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211230 |